Research programme: metabolic and lipid disorder therapeutics - Spherix

Alternative Names: SPX 100; SPX 10624258; SPX 723; SPX 7233801; SPX 8522876; SPX 8818309; SPX 8818440; SPX-106; SPX-106T

Latest Information Update: 16 Jul 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator University of Kentucky Research Foundation
Developer Spherix
Class Hexoses; Small molecules
Mechanism of Action Iron chelating agents; Lipid modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Abdominal aortic aneurysm; Atherosclerosis; Diabetes mellitus; Dyslipidaemias; Metabolic syndrome; Obesity

Most Recent Events

16 Jul 2016 No recent reports of development identified for preclinical development in Abdominal-aortic-aneurysm in USA
16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA
16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.